Health Care Equipment

Endra Life Sciences

Endra Life Sciences released FY2026 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.0932 (forecast USD -1.23)

Endra Life Sciences released FY2025 earnings on March 31 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -8.9291 (forecast USD -6.59)

Endra Life Sciences released FY2025 Q4 earnings on March 31 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.8539 (forecast USD -1.23)

Endra Life Sciences released FY2025 9 Months earnings on November 14 (EST), actual revenue USD 0, actual EPS USD -5.6681

Endra Life Sciences released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.0965 (forecast USD -1.95)

ENDRA Completes Private Placement Financing and Acquires HYPE Tokens for New Digital Asset Strategy

Endra Life Sciences released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -3.5493

Endra Life Sciences released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.7095 (forecast USD -2.27)

ENDRA Life Sciences Reports Q2 2025 Revenue at Zero

ENDRA Launches TAEUS Liver Device Clinical Study

Endra Life Sciences released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.8586 (forecast USD -3.91)

ENDRA Life Sciences Reports Q1 2025 Net Loss of $1 Million

Ascendiant Capital Maintains BUY Rating on ENDRA Life Sciences and Adjusts Target Price Down

Endra Life Sciences released FY2024 Q4 earnings on March 31 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -7.6883 USD (forecast -143.5001 USD)

Endra Life Sciences released FY2024 annual earnings on March 31 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -56.9401 USD (forecast -1.661 K USD)

ENDRA Life Sciences Announces New Strategy to Advance TAEUS System for Early Identification of Metabolic Diseases

ENDRA Life Sciences Expected Loss of $4.10 per Share, Analyst Rating Buy

Endra Life Sciences released FY2024 Q3 earnings on November 15 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -9.54 USD (forecast -62.3 USD)

Endra Life Sciences released FY2024 Cumulative 3Q Earnings on November 15 (EST), Revenue: 0, EPS: -152.5239

ENDRA Life Sciences Company Quarterly Earnings Release

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

DOMO

CLOU

DTCR

DOMO (Domo, Inc.) will announce its Q1'26 earnings on May 21 at 8:00 AM ET. The revenue estimate is $79.65 million, with an anticipated EPS of $(0.07). Previous quarters showed a revenue surprise ranging from +1.25% to +3.04%. EPS surprises were significantly higher, with increases up to 194.74%.

TradingView

Domo-B

Global X Cloud Computing ETF

Global X Data Center & Dgtl Infrs ETF

Factset Research

DOMO Q1'26 Earnings: revenue estimate is 79.65M USD

ASBP

BEAT

NDRA

SBIO

LABU

In Wednesday's pre-market session, Immutep (NASDAQ:IMMP) saw a significant gain of 135.4%, reaching $0.74, with a market cap of $46.3 million. Other gainers included ENDRA Life Sciences (NASDAQ:NDRA) up 13.1% to $5.61, and Medicus Pharma (NASDAQ:MDCX) up 12.15% to $0.45. Conversely, Aspire Biopharma Holdings (NASDAQ:ASBP) dropped 28.2% to $0.85, while HeartBeam (NASDAQ:BEAT) fell 25.36% to $0.9. Overall, several stocks experienced notable fluctuations in their market values during this session.

benzinga_article

Aspire Biopharma

HeartBeam

Medicus Pharma

Immutep

ALPS Medical Breakthrough

Health Care Select Sector SPDR

SPDR S&P Biotech

SPDR S&P Health Equip

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

iShares US Medical Devices

iShares US Pharma

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

VanEck Biotech ETF

VG Health

Liminatus Pharma

Brainsway

Acurx Pharmaceuticals

Curanex Pharmaceuticals

Wellgistics Health

Clearmind Medicine

Aligos Therapeutics

Immutep Ltd

ENDRA LIFE SCIENCES INC

MEDICUS PHARMA LTD C/WTS 15/11/2029(TO PUR COM)

LIMINATUS PHARMA INC C/WTS 30/04/2030 (TO PUR COM)

ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM)

HEARTBEAM INC C/WTS 31/10/2026 (TO PUR COM)

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

OLSI

MDLS

Denver Life Sciences announced that serial entrepreneur Mike Iiams has invested in the company and joined its board. DLS aims to address chronic dehydration, a health risk affecting 72 million Americans annually, by using advanced sensors to measure hydration levels in under 45 seconds. The company offers a modern alternative to outdated hydration measurement methods, providing personalized insights through a mobile app. Iiams, motivated by personal experiences, sees DLS's mission and technology as a significant advancement in health and wellness.

prnewswire

Origin Life Sciences

MDNA Life Sciences, Inc.

11:09 ETSerial Entrepreneur Invests in Hydration Mission

Earnings Watch

Endra Life Sciences | 10-K: FY2025 Revenue: USD 0

Endra Life Sciences | 8-K: FY2025 Revenue: USD 0

RCKT

In Friday's pre-market session, several health care stocks experienced notable movements. Pomdoctor (POM) shares surged 33% to $0.36, while OnKure Therapeutics (OKUR) rose 19.17% to $5.47. Other gainers included GlucoTrack (GCTK) up 17.42% to $1.28, Lantern Pharma (LTRN) up 12.44% to $2.35, and Rocket Pharmaceuticals (RCKT) up 11.3% to $5.22. Conversely, ENDRA Life Sciences (NDRA) fell 12.4% to $4.02, Universe Pharmaceuticals (UPC) dropped 10.26% to $2.1, and Acumen Pharmaceuticals (ABOS) declined 10.2% to $2.29. Quoin Pharmaceuticals (QNRX) and Zenas BioPharma (ZBIO) also saw declines following their Q4 earnings reports.

Rocket Pharma

Quoin Pharmaceuticals

Pomdoctor

Invesco Nasdaq Biotechnology ETF

Lantern Pharma

Acumen Pharmaceuticals

OnKure Therapeutics

Universe Pharmaceuticals

12 Health Care Stocks Moving In Friday's Pre-Market Session

NNNN

In Thursday's after-market session, Polyrizon (PLRZ) shares rose 11.3% to $14.61, while ENDRA Life Sciences (NDRA) increased by 5.26% to $4.2. Eledon Pharmaceuticals (ELDN) and High Tide (HITI) also saw gains of 3.97% and 3.29%, respectively. Conversely, Anbio Biotechnology (NNNN) fell 10.9% to $22.93, and Healthcare Triangle (HCTI) dropped 8.16% to $0.28. Other notable losers included Adlai Nortye (ANL) and OSR Holdings (OSRH), with declines of 8.12% and 5.4%.

Endra Life Sciences(NDRA.US)